Overview: Aspergillus Fumigatus IgG TestIntroduction: The Aspergillus Fumigatus IgG Test detects IgG antibodies to Aspergillus fumigatus, indicating exposure causing respiratory or allergic symptoms. Aligned with 2023 AAAAI guidelines, it uses an immunoassay for high specificity, aiding in allergy screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected fungal allergies.
Other Names: Aspergillus Fumigatus Antibody Assay, Fungal Allergy Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Fungal allergy testing began in the 1980s with skin tests. Aspergillus fumigatus IgG assays emerged in the 1990s, and by the 2000s, immunoassays improved specificity for allergic conditions.
Purpose: Diagnoses Aspergillus fumigatus-related allergies or infections, guides treatment, and monitors exposure in patients with respiratory or allergic symptoms.
Test Parameters: 1. Aspergillus Fumigatus IgG
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like wheezing or nasal congestion, and list medications like antihistamines.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document allergic or respiratory symptoms, history of fungal exposure, or family history of allergies. Include current medications, especially antihistamines or corticosteroids.
Consent: Written consent required, detailing the tests purpose, implications for allergy management, and potential need for antifungal or allergy therapy.
Procedural Considerations: Uses an immunoassay to measure Aspergillus fumigatus IgG antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants or antifungals may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm Aspergillus fumigatus exposure, prompting allergy management or antifungal therapy. Negative results may require skin prick testing.
Specialist Consultation: Consult an allergist for result interpretation. A pulmonologist referral is advised for respiratory involvement.
Additional Supporting Tests: Skin prick test, galactomannan test, or chest CT to confirm fungal allergy or infection.
Test Limitations: False negatives may occur with early exposure or immunosuppression. Results require clinical correlation.
References: AAAAI Allergy Guidelines, 2023; Journal of Allergy and Clinical Immunology, Greenberger PA, 2022.
